Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NEUROCRINE BIOSCIENCES INC incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto at Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu maturing fifth anniversary of the Closing Date.
- Instrument
- revolving credit
- Principal
- $1.0 billion
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto
- Rate
- Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu
- Maturity
- fifth anniversary of the Closing Date
- Event
- incurrence
Exact text from the filing
On May 14, 2026 (the “ Closing Date ”), the Company entered into a credit agreement (the “ Credit Agreement ”) with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (in such capacities, the “ Agent ”), and the lenders party thereto. The Credit Agreement provides for a five-year, $1.0 billion senior secured revolving credit facility (the “ Revolving Credit Facility ”).
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
NEUROCRINE BIOSCIENCES INC completed an acquisition involving Soleno Therapeutics, Inc. for $53.00 per Soleno Share (closed 2026-05-18).
- Action
- acquisition
- Counterparty
- Soleno Therapeutics, Inc.
- Consideration
- $53.00 per Soleno Share
- Closing
- 2026-05-18
Exact text from the filing
through Purchaser, commenced a tender offer to purchase all the outstanding shares of Soleno’s common stock, par value $0.001 per share (the “ Soleno Shares ”), at a price of $53.00 per Soleno Share (the “ Offer Price ”), in cash, without interest and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in the
View on SEC.gov